BioNTech reported third quarter 2026 revenue of €1.29 billion, exceeding consensus estimates of €1.04 billion. The strong performance was driven by the recognition of a €613.0 million milestone payment from Bristol Myers Squibb related to the pumitamig (BNT327) collaboration, which successfully offset a 35% year-over-year decline in COVID-19 vaccine revenues. The company returned to quarterly profitability with a net profit of €184.5 million, supported by aggressive cost management and pipeline prioritization despite rising R&D investments.
Key Highlights
- Total revenue of €1,289.2 million beat expectations as oncology milestone payments compensated for lower COVID-19 vaccine market demand.
- Diluted EPS reached €0.73, surpassing the €0.70 estimate, marking a recovery from the net loss recorded in the prior-year period.
- Research and development expenses increased 32% to €748.1 million, reflecting accelerated spending on late-stage antibody-drug conjugate (ADC) and immuno-oncology programs.
- Liquidity remained robust with €10.2 billion in cash and cash equivalents, providing a significant buffer for the company's multi-technology pipeline expansion.